CD38 and Miyoshi myopathy: Primary resistance to daratumumab has also been linked to CD38 receptor density.[38] There is a current focus on enhancing CD38 expression on MM cells in order to capitalize on the wide range of effective treatment options and improve overall efficacy.[11, 12] Consequently, the precise detection of measurable residual disease will gain greater significance for the expanding patient population, enabling them to benefit from emerging therapeutic alternatives.